Phospho-CHK2 (Thr68)抗体特异性结合抗原：抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而，抗体可通过与病毒或**的特异性结合，直接发挥中和病毒的作用。
产物编号xy- 3721R
英文名称Phospho-CHK2 (Thr68)
中文名称磷酸化细胞周期检测点激酶2抗体
别 名bA444G7; CHK2 checkpoint homolog; CHK2_HUMAN; Serine/threonine-protein kinase Chk2; CDS 1; CDS1; Checkpoint kinase 2; Checkpoint like protein CHK2; Chek 2; Chek2; Chk 2; CHK2 checkpoint homolog (S. pombe); CHK2 checkpoint homolog; HuCds 1; HuCds1; LFS 2; LFS2; PP1425; RAD 53; RAD53; Rad53 homolog; Serine/threonine protein kinase Chk2.
说 明 书100ul
产物类型磷酸化抗体
研究领域肿瘤 染色质和核信号 激酶和磷酸酶 表观遗传学
抗体来源搁补产产颈迟
克隆类型笔辞濒测肠濒辞苍补濒
Phospho-CHK2 (Thr68)抗体交叉反应 Human, Mouse, Rat, Dog, Pig, Cow, Horse,
产物应用WB=1:500-2000 ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量61kDa
细胞定位细胞核
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated Synthesised phosphopeptide derived from human CHK2 around the phosphorylation site of Thr68:VS(p-T)QE
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Phospho-CHK2 (Thr68)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产物介绍产补肠办驳谤辞耻苍诲:
In response to DNA damage and replication blocks, cell cycle progression is halted through the control of critical cell cycle regulators. The protein encoded by this gene is a cell cycle checkpoint regulator and putative tumor suppressor. It contains a forkhead-associated protein interaction domain essential for activation in response to DNA damage and is rapidly phosphorylated in response to replication blocks and DNA damage. When activated, the encoded protein is known to inhibit CDC25C phosphatase, preventing entry into mitosis, and has been shown to stabilize the tumor suppressor protein p53, leading to cell cycle arrest in G1. In addition, this protein interacts with and phosphorylates BRCA1, allowing BRCA1 to restore survival after DNA damage. Mutations in this gene have been linked with Li-Fraumeni syndrome, a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53. Also, mutations in this gene are thought to confer a predisposition to sarcomas, breast cancer, and brain tumors. This nuclear protein is a member of the CDS1 subfamily of serine/threonine protein kinases. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Apr 2012]
Function:
Serine/threonine-protein kinase which is required for checkpoint-mediated cell cycle arrest, activation of DNA repair and apoptosis in response to the presence of DNA double-strand breaks. May also negatively regulate cell cycle progression during unperturbed cell cycles. Following activation, phosphorylates numerous effectors preferentially at the consensus sequence [L-X-R-X-X-S/T]. Regulates cell cycle checkpoint arrest through phosphorylation of CDC25A, CDC25B and CDC25C, inhibiting their activity. Inhibition of CDC25 phosphatase activity leads to increased inhibitory tyrosine phosphorylation of CDK-cyclin complexes and blocks cell cycle progression. May also phosphorylate NEK6 which is involved in G2/M cell cycle arrest. Regulates DNA repair through phosphorylation of BRCA2, enhancing the association of RAD51 with chromatin which promotes DNA repair by homologous recombination. Also stimulates the transcription of genes involved in DNA repair (including BRCA2) through the phosphorylation and activation of the transcription factor FOXM1. Regulates apoptosis through the phosphorylation of p53/TP53, MDM4 and PML. Phosphorylation of p53/TP53 at 'Ser-20' by CHEK2 may alleviate inhibition by MDM2, leading to accumulation of active p53/TP53. Phosphorylation of MDM4 may also reduce degradation of p53/TP53. Also controls the transcription of pro-apoptotic genes through phosphorylation of the transcription factor E2F1. Tumor suppressor, it may also have a DNA damage-independent function in mitotic spindle assembly by phosphorylating BRCA1. Its absence may be a cause of the chromosomal instability observed in some cancer cells.
Subunit:
Homodimer. Homodimerization is part of the activation process but the dimer may dissociate following activation. Interacts with PML. Interacts with TP53. Interacts with RB1; phosphorylates RB1. Interacts with BRCA1. Interacts (phosphorylated at Thr-68) with MDC1; requires ATM-mediated phosphorylation of CHEK2. Interacts with TP53BP1; modulates CHEK2 phosphorylation at Thr-68 in response to ionizing radiation. Interacts with CDC25A; phosphorylates CDC25A and mediates its degradation in response to ionizing radiation. Interacts with CUL1; mediates CHEK2 ubiquitination and regulation.
Subcellular Location:
Isoform 2: Nucleus. Note=Isoform 10 is present throughout the cell.
Isoform 4: Nucleus.
Isoform 7: Nucleus.
Isoform 9: Nucleus.
Isoform 12: Nucleus.
Nucleus, PML body. Nucleus, nucleoplasm. Note=Recruited into PML bodies together with TP53.
Tissue Specificity:
High expression is found in testis, spleen, colon and peripheral blood leukocytes. Low expression is found in other tissues.
Post-translational modifications:
Phosphorylated. Phosphorylated at Ser-73 by PLK3 in response to DNA damage, promoting phosphorylation at Thr-68 by ATM and the G2/M transition checkpoint. Phosphorylation at Thr-68 induces homodimerization. Autophosphorylates at Thr-383 and Thr-387 in the T-loop/activation segment upon dimerization to become fully active and phosphorylate its substrates like for instance CDC25C. DNA damage-induced autophosphorylation at Ser-379 induces CUL1-mediated ubiquitination and regulates the pro-apoptotic function. Phosphorylation at Ser-456 also regulates ubiquitination. Phosphorylated by PLK4.
Ubiquitinated. CUL1-mediated ubiquitination regulates the pro-apoptotic function. Ubiquitination may also regulate protein stability (PubMed:17715138).
Phospho-CHK2 (Thr68)抗体（antibody,
Ab）是由效应B细胞（效应**B细胞）分泌，机体用于抵御外来物质，如病毒，**等抗原，结构呈“驰”字型的球状蛋白质，仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质，均被称作抗原，因此对于抗抗体（能够结合抗体的抗体）来说，抗体本身也是一种抗原物质。
Phospho-CHK2 (Thr68)抗体普通抗体重链和轻链的结构
重链结构：普通的**球蛋白具有2条重链（H链），分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型，对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构： 普通**球蛋白具有2条轻链（L链），分子质量约25kDa，有κ链和λ链两种亚型，这两种轻链决定了Ig的亚型类别（IgG1，IgG2，IgG3，IgG4）。一个天然的Ig分子两条轻链总是相同的，但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同，正常人血清**球蛋白κ链：λ链约为2：1，而在小鼠的比例为20：1。
2.2抗体Fab段和Fc段
滨驳骋经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应；经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段（fragment of antigen binding，Fab），相当于抗体分子的两个臂，由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段（fragment crystallizable，Fc）相当于Ig的CH2和CH3结构域，是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区，以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域，相当于Y字结构下面那一部分。
合格 TRIM29 (acetyl K116) 乙酰化TRIM29蛋白抗体
合格 TRIM38 TRIM38蛋白抗体
合格 TRIM42 TRIM42蛋白抗体
合格 TRIM43B TRIM43B蛋白抗体
合格 TRIM45 TRIM45蛋白抗体
合格 TRIM49 TRIM49蛋白抗体
合格 TRIM50C TRIM50C蛋白抗体
合格 KLB KLB蛋白抗体
合格 KLC2 驱动蛋白轻链2抗体
合格 KLC4 驱动蛋白轻链4抗体
合格 合格 KLHDC1 KLHDC1蛋白抗体
合格 KLHDC10 KLHDC10蛋白抗体
合格 KLHDC2 肝癌相关抗原33抗体
合格 KLHDC4 KLHDC4蛋白抗体
合格 合格 KLHDC7B KLHDC7B蛋白抗体
合格 KLHDC8B KLHDC8B蛋白抗体
合格 合格 KLHL15 Kelch样蛋白15抗体
合格 KLHL18 Kelch样蛋白18抗体
合格 KLHL2 Kelch样蛋白2抗体
合格 合格 KLHL30 Kelch样蛋白30抗体
合格 KLHL38 Kelch样蛋白38抗体
合格 KLHL4 Kelch样蛋白4抗体
合格 KLHL5 Kelch样蛋白5抗体
合格 KLHL6 Kelch样蛋白6抗体
合格 DNA Ligase IV DNA连接酶4抗体
合格 KLRF2 杀伤细胞凝集素样受体F2抗体
合格 KLRG2 自然杀伤凝集素样受体G2抗体
合格 KMT1D 赖氨酸N甲基转移酶1D/EHMT1抗体
合格 KMT2G 组蛋白赖氨酸N-甲基2G抗体
合格 KMT3C 组蛋白赖氨酸N-甲基转移酶3C抗体
合格 合格 KMT5A 组蛋白H4 K20甲基转移酶抗体
合格 KPC2 E3泛素蛋白连接酶亚基KPC2抗体
合格 KPNA3 KPNA3蛋白抗体
合格 KPNA4 KPNA4蛋白抗体